• Abstract Submission Rules and Guidelines


    1. There is a maximum of 3 image uploads allowed. The only accepted file formats are JPG, JPEG, PNG, and GIF. There are four sections: Background, Methods Results, and Conclusions. You are allowed a TOTAL of 1900 characters for all four sections combined. Please note that each image counts as 500 characters.

    2. Abstracts that have been previously published or presented will NOT be eligible for presentation at SCAI. If your abstract is accepted for presentation at another meeting or published prior to the SCAI 2018 Scientific Sessions you must notify SCAI immediately to withdraw your abstract.

    3. Case Studies will NOT be accepted or considered for presentation at the SCAI 2018 Scientific Sessions.

    4. Abstract submissions must fit into one of the following categories:

      • Acute Coronary Syndromes, Myocardial Infarction, Thrombectomy and Vulnerable Plaque
      • Adult Congenital
      • Angiogenesis, Myogenesis, Cell Therapy and Gene Therapy
      • Complex PCI, Restenosis, Left Main & Multi-Vessel Intervention
      • Contrast Agents
      • Endovascular and Peripheral Interventions (Including Neurovascular and Carotid)
      • Imaging: CT, MR and Non-Invasive Imaging
      • Intravascular Imaging (IVUS/OCT/NIR/Other) and Physiology (FFR/iFR/IMR/other)
      • Left Main & Multi-Vessel Intervention
      • Miscellaneous
      • Pediatric
      • Pharmacotherapy
      • Quality Improvement
      • Stents (including DES)
      • Valvular Interventions and Structural Heart Disease
      • Vascular Access and Arterial Closure Devices

    5. All revisions must be made by the abstract submission deadline.

    6. Requests to withdraw an abstract must be submitted in writing to meetings@scai.org by January 31, 2018.

    7. Abstract grading is blind. Please do not include author or institution names in the body of your abstract.

    8. Guidelines for presentations will be provided to authors of accepted abstracts upon notification of acceptance.

    9. Abstract acceptance notifications will be e-mailed to the addresses provided for the presenting authors in late January.

    10. Media coverage of abstracts and clinical trials presented at SCAI 2018 Scientific Sessions is prohibited until the start time of the presentation or the beginning of the session containing the research. The embargo on poster presentations lifts when the poster session containing the poster opens for viewing.


    1.  Investigators should not submit the same research; applications that appear to be replicate versions of a single study will be rejected.

    2.  Follow all instructions for completing the submission. Be sure to structure the content into Background, Methods, Results, and Conclusion sections

    3. Any abstract presenting data that in whole or part is contained in a Late-Breaking Clinical Science presentation submission that was accepted to be presented in the SCAI Annual Scientific Sessions general abstract program cannot be presented in the regular program and must be withdrawn if that trial is accepted for presentation as a Late-Breaking Clinical Science presentation.

    4. Abstracts are not eligible for consideration if the data has been presented or published at a U.S. or international meeting held before the SCAI Annual Scientific Sessions.

    5. The SCAI Program Committees endorse the position of the American Association for the Advancement for Science in requiring assurances of the responsible use of animals in research. All submissions for consideration must be in compliance with the guidelines.

    6. Each presenting author will be asked to comply with the SCAI Disclosure Policy. An indication of the relationship, the associated commercial entity, and level of support is required for each presenting author. All presenters at SCAI's Annual Scientific Sessions must display a slide at the beginning of their presentation indicating disclosure information as applicable, or that they have nothing to disclose.

    7. The submitter acts on behalf of all co-authors and in submitting an abstract/late-breaking clinical trial, transfers to SCAI the copyright and all other rights in the material comprising the application if the application is accepted. Co-authors reserve the following:

      • All proprietary rights other than copyright, such as patent rights; and
      • The right to use all or part of the application in future works of their own. The meeting organizers, as the holder of the copyright on the accepted application, reserve all rights of reproduction, distribution, performance, display, and the right to create derivative works in both print and digital formats.

    8. In light of increased attention to the manner in which research results (particularly those affecting the stock of publicly-traded companies) are made public, SCAI requires all authors to read and comply with the SCAI embargo policy. Anyone determined by SCAI to have violated the embargo policies may be withdrawn from the program or sanctioned as deemed necessary.

      • All applications submitted are disclosed to members of the peer review selection committee, as well as to SCAI employees and contractors as necessary in connection with the annual meeting. Those applications that are accepted for presentation are summarized for publication after the Annual Scientific Sessions and are not publicly available to the public in advance of the meetings. Applications not accepted for presentation are not summarized and are ordinarily not disclosed outside of SCAI and persons associated with the selection process (i.e., the peer review committee). Notwithstanding these policies and procedures, SCAI is not subject to any confidentiality requirements with respect to submitted applications. In addition, compliance with any disclosure or nondisclosure requirements that apply to researchers or research sponsors (whether under federal securities laws, contract agreement, or otherwise) is the sole responsibility of the researcher and/or sponsor, and not SCAI.
      • All authors, presenters, company sponsors, attendees, journalists and/or anyone with knowledge of embargoed content must comply with SCAI embargo policies, which state that scientific study results presented during the Annual Scientific Sessions must not be released publicly prior to the time of presentation at the Annual Scientific Sessions or the SCAI-sponsored press conference, whichever comes first.
      • Some, though not all, Late Breaking Clinical Science presentations may be selected for a SCAI press conference. Late Breaking Clinical Science presentations not selected for a press conference remain under embargo until the time of the presentation.
      • Presentation or discussion of scientific research results at satellite meetings or press conferences prior to the scheduled Annual Scientific Sessions scientific presentation is strictly forbidden.
      • Investigator meetings: The only exception to the above-mentioned embargo rule are closed investigator meetings for participants in the trial. The Annual Scientific Sessions Committees may ask you to supply investigator meeting date/time/location information if your submission is accepted.
      • In the event that media representatives contact authors, presenters and/or company sponsors, any information must be given with the understanding that scientific research results are to remain under embargo until the time of presentation or SCAI-sponsored press conference. Responsibility for information shared in this manner rests solely with the disclosing authors, presenters and/or company sponsors.
      • Authors, presenters, company sponsors, attendees, journalists, public relations firms, and/or anyone with knowledge of embargoed content must seek prior SCAI approval before publicly revealing any embargoed content for any reason. The SCAI leadership, press staff, and meeting co-chairs will be available to work with the disclosing party to develop an acceptable release of the required information if specific disclosures (e.g., SEC requirements) must be met or in the case of public health concerns.


    Please contact SCAI Senior Meetings Manager Rachel Pham at rpham@scai.org or 202.741.9960.